Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Medicenna Therapeutics Corp ( (TSE:MDNA) ) has shared an announcement.
Medicenna Therapeutics Corp announced that its President and CEO, Dr. Fahar Merchant, will present at the Jones Healthcare and Technology Innovation Conference in Las Vegas. This participation highlights Medicenna’s active engagement with investors and industry stakeholders, potentially enhancing its visibility and strategic positioning in the immunotherapy sector.
More about Medicenna Therapeutics Corp
Medicenna Therapeutics Corp is a clinical-stage immunotherapy company specializing in the development of Superkines targeting cancer and autoimmune diseases. The company focuses on creating novel, highly selective versions of IL-2, IL-4, and IL-13 Superkines, as well as first-in-class Empowered Superkines. Their products include MDNA11, a next-generation IL-2 Superkine, and bizaxofusp, an IL-4 Empowered Superkine, which have shown promise in treating various forms of cancer and autoimmune conditions.
YTD Price Performance: -38.36%
Average Trading Volume: 63,589
Technical Sentiment Signal: Buy
Current Market Cap: C$76.65M
See more data about MDNA stock on TipRanks’ Stock Analysis page.